BC Extra | Nov 30, 2018
Company News

Management tracks: Inflazome, Clementia

Two weeks after raising €40 million ($45.7 million) in a series B round in preparation for its first clinical trials which are slated for next year, Inflazome Ltd. (Dublin, Ireland) hired Thomas Jung as its...
BioCentury | Jul 25, 2016
Product Development

Collecting CAR parts

While CAR T cell therapies have produced impressive response rates in blood cancers, the approach has so far shown limited effect in solid tumors, partly due to poor localization of T cells in tumor sites....
BC Week In Review | Jul 18, 2016
Company News

Delenex, Cell Medica deal

Cell Medica acquired Delenex. Cell Medica plans to use Delenex’s PENTRA antibody fragment platform to develop next-generation chimeric antigen receptor (CAR)-modified cellular immunotherapies to treat solid tumors. Delenex’s operations will be renamed Cell Medica Switzerland...
BC Extra | Jul 13, 2016
Company News

Cell Medica acquiring Delenex

Cell Medica Ltd. (London, U.K.) is acquiring Delenex Therapeutics AG (Zurich, Switzerland) for undisclosed terms. Cell Medica plans to use Delenex's PENTRA antibody fragment platform to develop next-generation chimeric antigen receptor (CAR)-modified cellular immunotherapies. Delenex's...
BC Week In Review | Jul 13, 2015
Clinical News

Delenex preclinical data

In a mouse xenograft model of glioma, DLX1008 significantly improved survival and inhibited tumor growth vs. controls. Next year, Delenex plans to start Phase I/II testing of the monovalent antibody fragment against VEGF-A to treat...
BC Week In Review | Jul 13, 2015
Clinical News

Delenex preclinical data

In a mouse model of Kaposi’s sarcoma, intraperitoneal 15 mg/kg DLX1008 given 5 days per week for 3 weeks significantly reduced tumor growth vs. an unrelated control single-chain antibody fragment (p<=0.004). Next year, Delenex plans...
BC Week In Review | May 4, 2015
Clinical News

DLX105 IV: Phase II data

A double-blind, placebo-controlled Phase II trial in 24 healthy volunteers showed that 3 doses levels of IV DLx10 5 produced “effective and fast tissue distribution.” In a subsequent open-label trial in 6 patients with flaring...
BioCentury | Oct 20, 2014
Emerging Company Profile

Rogne: Penetrating peptides

Rogne Bioscience Inc. is developing a topical formulation of a naturally occurring human peptide that inhibits production of inflammatory cytokines to treat mild to moderate psoriasis without the side effects of topical steroids or injectable...
BC Week In Review | Sep 15, 2014
Clinical News

DLX105 topical: Phase II data

A double-blind, placebo-controlled, Austrian and German Phase II trial in 59 patients with mild to moderate plaque psoriasis showed twice-daily topical 0.5% DLx10 5 for 4 weeks led to no significant clinical improvements. However, gene...
BC Extra | Sep 13, 2014
Clinical News

Delenex's DLX105 misses in psoriasis Phase II

Delenex Therapeutics AG (Zurich, Switzerland) said DLX105 led to no significant clinical improvements in a Phase II trial in mild to moderate plaque psoriasis. The co-primary efficacy endpoints were local Psoriasis Area Severity Index (PASI)...
Items per page:
1 - 10 of 25
BC Extra | Nov 30, 2018
Company News

Management tracks: Inflazome, Clementia

Two weeks after raising €40 million ($45.7 million) in a series B round in preparation for its first clinical trials which are slated for next year, Inflazome Ltd. (Dublin, Ireland) hired Thomas Jung as its...
BioCentury | Jul 25, 2016
Product Development

Collecting CAR parts

While CAR T cell therapies have produced impressive response rates in blood cancers, the approach has so far shown limited effect in solid tumors, partly due to poor localization of T cells in tumor sites....
BC Week In Review | Jul 18, 2016
Company News

Delenex, Cell Medica deal

Cell Medica acquired Delenex. Cell Medica plans to use Delenex’s PENTRA antibody fragment platform to develop next-generation chimeric antigen receptor (CAR)-modified cellular immunotherapies to treat solid tumors. Delenex’s operations will be renamed Cell Medica Switzerland...
BC Extra | Jul 13, 2016
Company News

Cell Medica acquiring Delenex

Cell Medica Ltd. (London, U.K.) is acquiring Delenex Therapeutics AG (Zurich, Switzerland) for undisclosed terms. Cell Medica plans to use Delenex's PENTRA antibody fragment platform to develop next-generation chimeric antigen receptor (CAR)-modified cellular immunotherapies. Delenex's...
BC Week In Review | Jul 13, 2015
Clinical News

Delenex preclinical data

In a mouse xenograft model of glioma, DLX1008 significantly improved survival and inhibited tumor growth vs. controls. Next year, Delenex plans to start Phase I/II testing of the monovalent antibody fragment against VEGF-A to treat...
BC Week In Review | Jul 13, 2015
Clinical News

Delenex preclinical data

In a mouse model of Kaposi’s sarcoma, intraperitoneal 15 mg/kg DLX1008 given 5 days per week for 3 weeks significantly reduced tumor growth vs. an unrelated control single-chain antibody fragment (p<=0.004). Next year, Delenex plans...
BC Week In Review | May 4, 2015
Clinical News

DLX105 IV: Phase II data

A double-blind, placebo-controlled Phase II trial in 24 healthy volunteers showed that 3 doses levels of IV DLx10 5 produced “effective and fast tissue distribution.” In a subsequent open-label trial in 6 patients with flaring...
BioCentury | Oct 20, 2014
Emerging Company Profile

Rogne: Penetrating peptides

Rogne Bioscience Inc. is developing a topical formulation of a naturally occurring human peptide that inhibits production of inflammatory cytokines to treat mild to moderate psoriasis without the side effects of topical steroids or injectable...
BC Week In Review | Sep 15, 2014
Clinical News

DLX105 topical: Phase II data

A double-blind, placebo-controlled, Austrian and German Phase II trial in 59 patients with mild to moderate plaque psoriasis showed twice-daily topical 0.5% DLx10 5 for 4 weeks led to no significant clinical improvements. However, gene...
BC Extra | Sep 13, 2014
Clinical News

Delenex's DLX105 misses in psoriasis Phase II

Delenex Therapeutics AG (Zurich, Switzerland) said DLX105 led to no significant clinical improvements in a Phase II trial in mild to moderate plaque psoriasis. The co-primary efficacy endpoints were local Psoriasis Area Severity Index (PASI)...
Items per page:
1 - 10 of 25